News and Events

DeOvo™ anti-louse product successfully completes Phase I safety study in human volunteers

21/05/2007 | Press Releases

Hatchtech’s head louse control product has completed its first human trials finding no side effects or other adverse events associated with the product. 32 patients were treated at escalating dose levels and carefully monitored via observation, blood tests and electrocardiography. The trial was conducted by Q-Pharm in Queensland from February to April 2007.

Download PDF